ERASCA INC. news, videos and press releases
For more news please use our advanced search feature.
ERASCA INC. - More news...
ERASCA INC. - More news...
- Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
- Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results
- Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference
- Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Erasca Reports Third Quarter 2024 Business Updates and Financial Results
- Erasca to Present at Upcoming Investor Conferences
- Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
- Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
- Erasca to Present at Upcoming Investor Conferences in September
- Erasca Reports Second Quarter 2024 Business Updates and Financial Results
- Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma
- Erasca to Present at Upcoming Investor Conferences in June
- Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
- Erasca Announces Pricing of Underwritten Offering of Common Stock
- Erasca Reports First Quarter 2024 Business Updates and Financial Results
- Erasca to Present at the Bank of America Health Care Conference
- Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
- Erasca Announces $45 Million Oversubscribed Private Placement Financing
- Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
- Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
- Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
- Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
- Erasca Reports Third Quarter 2023 Financial Results and Business Updates
- Erasca to Present at Upcoming Investor Conferences in November
- Erasca to Present at the Cantor Global Healthcare Conference
- Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
- Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors
